Skip to main content
OpenTrials
Completed

NCT Number: NCT00000224

Alternate-Day Buprenorphine. Phase V - 6

The purpose of this study is to evaluate buprenorphine blockade challenge.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Opioid-related Disorders Chemically-Induced Disorders Mental Disorders Narcotic-Related Disorders Substance-Related Disorders

Age range

30 year–49 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Treatment Research Center

Burlington, Vermont, 05401, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Please contact site for information.

Treatment and study plan

buprenorphine

Drug

Primary outcomes

  1. Drug use

  2. Opioid withdrawal

  3. Subjective dose estimate

  4. Drug effect characteristics: ARCI

  5. Physiological changes in: pupil diameter

  6. Physiological changes in: blood pressure

  7. Physiological changes in: heart rate

  8. Physiological changes in: respiration

  9. Physiological changes in: bup plasma levels

Sponsors and collaborators

Lead sponsor

National Institute on Drug Abuse (NIDA)

Nih

Collaborators

  • University of Vermont

Registry information

Official study title

Alternate-Day Buprenorphine. Phase V

Important dates

Study start
1993
First posted
Sep 21, 1999
Registry last updated
Jun 24, 2005

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.